24 results match your criteria: "G. Garibaldi Hospital[Affiliation]"

Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients.

ESMO Open

January 2025

Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy. Electronic address:

Background: Daratumumab-refractory multiple myeloma (Dara-R MM) presents a significant treatment challenge. This study aimed to evaluate the efficacy and survival outcomes of elotuzumab, pomalidomide, and dexamethasone (EloPd) in a large, real-world cohort of patients with Dara-R MM, with particular focus on progression-free survival (PFS) and overall survival (OS).

Materials And Methods: This retrospective analysis included 247 Dara-R MM patients treated with EloPd.

View Article and Find Full Text PDF
Article Synopsis
  • - The ELOQUENT-3 trial found that the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) is more effective and safer than pomalidomide and dexamethasone (Pd) for treating relapsed/refractory multiple myeloma (RRMM) patients who have undergone at least two prior therapies.
  • - An 18-month follow-up of 319 RRMM patients treated with EloPd in Italy revealed that 66.4% experienced disease progression or death, with median progression-free survival and overall survival recorded at 7.5 and 19.2 months, respectively.
  • - While EloPd remains a viable treatment option,
View Article and Find Full Text PDF

Objectives: to describe the results of a pilot population-based perinatal mortality surveillance system, with regards to stillbirths; to study maternal, obstetric, and foetal characteristics, evaluating risk factors and understanding causes.

Design: a cross-sectional study was conducted on incident cases of stillbirths collected by the surveillance system from July 2017 to June 2019 in three Italian Regions (Lombardy, Tuscany, and Sicily).

Setting And Participants: data on stillbirths, resulting from the in-hospital multidisciplinary audits, organised using the Significant Event Audit methodology, were analysed.

View Article and Find Full Text PDF
Article Synopsis
  • - In the ELOQUENT-3 trial, the combination therapy of elotuzumab, pomalidomide, and dexamethasone (EloPd) showed better results for treating relapsed/refractory multiple myeloma (RRMM) compared to pomalidomide and dexamethasone alone, leading to its approval for specific patients.
  • - A real-world study of 200 RRMM cases in Italy confirmed similar effectiveness and manageable side effects for EloPd, with a 55.4% overall response rate and a median progression-free survival of 7 months, though these were lower than results from the ELOQUENT-3 trial.
  • - Factors like the number of previous
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the use of urinary S100B protein as a biomarker for early detection of brain injury in infants suffering from hypoxic-ischemic encephalopathy (HIE), comparing it to brain MRI results.
  • Urine samples were collected in a cohort of 74 HIE neonates receiving therapeutic hypothermia, with S100B concentrations showing a correlation with MRI patterns at the first urine sample.
  • High levels of S100B in urine after birth can reliably predict brain injury, suggesting it could be valuable for clinical decision-making regarding HIE treatment.
View Article and Find Full Text PDF

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers.

View Article and Find Full Text PDF

Objectives: The early detection of preterm infants (PI) at risk for intraventricular hemorrhage (IVH) and neurological sequelae still constitutes an unsolved issue. We aimed at validating the role of S100B protein in the early diagnosis and prognosis of IVH in PI by means of cerebral ultrasound (CUS) and magnetic resonance imaging (MRI) today considered standard of care procedures.

Methods: We conducted an observational case-control study in 216 PI of whom 36 with IVH and 180 controls.

View Article and Find Full Text PDF

Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis.

Ann Hematol

March 2021

Policlinico Paolo Giaccone, Unit of Haematology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.

The primary aim of this study was to describe the use of primary anti-infective prophylaxis (AP) in common clinical practice in patients affected by immune thrombocytopenia (ITP) and treated with RTX. Population studied consisted of patients affected by ITP (age ≥ 18 years) who had received at least one dose of RTX from January 2008 to June 2018. Five Italian haematology centres participated in the current study.

View Article and Find Full Text PDF

Objectives: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only.

Methods: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study.

Results: At an unadjusted univariate analysis, a significant death risk reduction was observed favoring IB (IDELA-R vs IB HR = 0.

View Article and Find Full Text PDF

Background Perinatal asphyxia is a major cause of mortality and morbidity in neonates: The aim of the present study was to investigate, by means of longitudinal assessment of urinary S100B, the effectiveness of hypothermia, in infants complicated by perinatal asphyxia and hypoxic-ischemic encephalopathy. Methods We performed a retrospective case-control study in 108 asphyxiated infants, admitted to nine tertiary departments for neonatal intensive care from January 2004 to July 2017, of whom 54 underwent hypothermia treatment and 54 did not. The concentrations of S100B protein in urine were measured using an immunoluminometric assay at first urination and 4, 8, 12, 16, 20, 24, 48, 72, 96, 108 and 120 h after birth.

View Article and Find Full Text PDF

Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome. Patients were grouped into 5 categories: efficacy issues: 1 TPO-RA failure; loss of response; non-efficacy issues: platelet fluctuations; patient's preference; adverse event development. Either one TPO-RA sequence was analyzed at 3 month and at last follow-up.

View Article and Find Full Text PDF

Background: Perinatal asphyxia (PA) is a leading cause of mortality and morbidity in newborns: its prognosis depends both on the severity of the asphyxia and on the immediate resuscitation to restore oxygen supply and blood circulation. Therefore, we investigated whether measurement of S100B, a consolidated marker of brain injury, in salivary fluid of PA newborns may constitute a useful tool for the early detection of asphyxia-related brain injury.

Methods: We conducted a cross-sectional study in 292 full-term newborns admitted to our NICUs, of whom 48 suffered PA and 244 healthy controls admitted at our NICUs.

View Article and Find Full Text PDF

Serous cystadenocarcinoma of the pancreas with portal thrombosis.

Clin Ter

October 2015

Service of Surgical Oncology, Department of Oncology, G.Garibaldi Hospital, Catania, Italy.

Serous cystadenocarcinoma of the pancreas is a rare entity. We report on a primary tumor of the pancreas in a 74-year-old male. Computerized tomography showed an abdominal mass within pancreatic head, portal vein infiltration and absence of metastatic lesions.

View Article and Find Full Text PDF

Mesenteric cysts (MC) are a rare surgical condition occurring approximately in 1/200.000-350.000.

View Article and Find Full Text PDF

Cerebral monitoring constitutes an emerging issue in perinatal medicine. Near Infrared Spectroscopy (NIRS) monitors brain oxygenation status in sick infants although data in healthy infants are lacking. The present study investigates whether NIRS parameters change according to gestational age and correlate with S100B protein.

View Article and Find Full Text PDF

Near Infrared Spectroscopy (NIRS) is an emerging technique for brain oxygenation monitoring in newborns complicated by acute and chronic hypoxia. However, data regarding cerebral oxygenation normal values are still lacking and matter of debate. Therefore, we investigate whether NIRS parameters in healthy preterm/term infants are gestational age and delivery modalities dependent and correlate with standard monitoring parameters.

View Article and Find Full Text PDF

Data continue to grow regarding the safety and technical feasibility of laparoscopically assisted total mesorectal excision (TME). As this minimally invasive alternative to open colonic resection becomes more popular, it is inevitable that information on the benefits and complications associated with it will continue to expand. Portal vein thrombosis (PVT) has been reported after a variety of laparoscopic procedures.

View Article and Find Full Text PDF

Human milk S100B protein possesses important neurotrophic properties. However, in some conditions human milk is substituted by milk formulas. The aims of the present study were: to assess S100B concentrations in milk formulas, to verify any differences in S100B levels between preterm and term infant formulas and to evaluate the impact of industrial preparation at predetermined phases on S100B content.

View Article and Find Full Text PDF